U.S. hasn't sent essential seasonal flu data to WHO ahead of key vaccine meeting
Social Sharing
Seasonal flu vaccines need to be updated each year because the virus changes so frequently. But the U.S. hasn't contributed its information on what's spreading there since January, a World Health Organization (WHO) official said.
For seasonal influenza, which forced schools to shut down in some American states earlier this month, the data isn't being shared, Dr. Wenqing Zhang, head of the WHO's global influenza program, told journalists in a webinar on Wednesday.
The U.S. Centers for Disease Control and Prevention (CDC) and U.S. Food and Drug Administration (FDA) normally participate in global discussions hosted by WHO on influenza vaccinations twice a year.
Detailed seasonal flu information is important to monitor outbreaks globally and to inform which influenza strains should be included in vaccines for the Northern Hemisphere's following winter.
"Since 20th January, CDC has not yet reported into the WHO platform of Flunet and FluID," Zhang said, referring to two databases for influenza surveillance. As of last week, the U.S. was publicly releasing some flu information nationally.
When U.S. President Donald Trump was inaugurated on Jan. 20, he called for his country to leave WHO, starting in January 2026.
A WHO meeting is scheduled for next week in London to discuss the composition of influenza vaccines. So far, WHO says the U.S. has not indicated whether it will attend.
At the meeting, participants look at the data to come to a consensus on if the strains in the previous seasonal vaccine are still thought to work or if they need to be updated.
Kanta Subbarao says the U.S. also contributes expertise on vaccine effectiveness and key material used by vaccine manufacturers.
Subbarao, a pediatric infectious diseases specialist and influenza scientist now working at Laval University in Quebec City, served as director of WHO's Collaborating Centre for Influenza in Melbourne, Australia. It is one of five such centres for human influenza along with the U.S. CDC in Atlanta, England, China and Japan.
ERs under pressure from staffing shortages, respiratory illnesses
1 year ago
Duration 1:55
Staffing shortages and a surge in respiratory illnesses are putting pressure on Canada's emergency rooms, and experts are urging people to update their vaccinations.
"I think this is a very bad time for the flu vaccine," Subbarao said.
"The CDC and FDA are very actively involved normally in this process, so it's a little hard for me to fathom what it will look like without them."
Subbarao said the U.S. collaborating centre often receives influenza viruses from Canada and other parts of the Americas as well as Africa and parts of Asia.
U.S. makes a 'big difference'
Dr. Keiji Fukuda, a physician and epidemiologist who has attended influenza vaccine meetings and worked for both WHO and CDC, said it's crucial for U.S. experts to go.
"The interpretation of that data is so important," Fukuda said in an interview. "Hearing your peers discuss how they're looking at it may change how you look at it and these kinds of interactions are how we come up with the best formulations for vaccines."
U.S. participation is crucial to be able to accurately predict which influenza strains are going to be circulating in Canada, the U.S., and Mexico, said Angela Rasmussen, a virologist and principal research scientist at the Vaccine and Infectious Disease Organization in Saskatoon.
"Because the United States is so geographically large, because it is so populous, it really does make a big difference to know which of those influenza strains … are the ones that are going to be predominant and essentially win the race against the other influenza viruses," said Rasmussen. She studies a range of viral pathogens, including flu, and isn't participating in WHO's influenza vaccine meeting.
WHO's influenza surveillance program includes about 130 member states.
The CDC released weekly seasonal flu information on Feb. 14, as well as an update on cases of H5N1 avian influenza that has infected nearly 70 people in the U.S., including a death. Most of those infections have been among farm workers exposed to infected poultry or cows.
Doctors and scientists are watching closely to see if H5N1 or another type of influenza virus gains the ability to spread easily from person to person. That's caused previous global flu pandemics.
On Wednesday, the Canadian government announced the purchase of 500,000 doses of an H5N1 vaccine to help protect those most at risk, such as farm workers and people who handle live avian influenza virus in labs.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Global News
14 hours ago
- Global News
Ontario making it easier to poach U.S. health-care workers with registration change
Ontario is tweaking its registration rules for health-care professionals to make it easier to poach nurses from the United States and allow them to begin practising in the province sooner. On Thursday, the Ford government announced it would allow nurses and board-certified physicians to move to Ontario from the United States and begin working immediately while they apply to have their credentials recognized. According to a news release from the government, U.S.-licensed physicians, nurse practitioners, registered nurses and registered practical nurses can work for six months while transferring their qualifications and registering. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'By cutting the red tape that is delaying highly trained U.S.-licensed doctors and nurses from being able to live and work in Ontario, we are making bold strides to ensure Ontario patients receive timely and accessible care,' Health Minister Sylvia Jones said. 'These changes build on our government's historic action to reduce labour mobility barriers for health-care professionals within Canada, and will now make it faster and easier for American physicians and nurses to care for Ontario patients.' Story continues below advertisement The new registration rules for U.S.-based nurses and physicians mirror changes the province previously brought in for health-care professionals from other parts of Canada. The move would not exempt nurses or physicians from other work permit or immigration laws, but would make it easier to begin working in their field once they move to Ontario. The move comes as the Ford government continues its efforts to onshore Canadian products and supply chains as part of Canada's ongoing trade war with the United States. The province is looking to eliminate trade barriers with other parts of the country, has banned the sale of U.S alcohol and introduced a domestic manufacturing tax credit.
Winnipeg Free Press
16 hours ago
- Winnipeg Free Press
Who's in charge? CDC's leadership ‘crisis' apparent amid new COVID-19 vaccine guidance
WASHINGTON (AP) — There was a notable absence last week when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced in a 58-second video that the government would no longer endorse the COVID-19 vaccine for healthy children or pregnant women. The director of the Centers for Disease Control and Prevention — the person who typically signs off on federal vaccine recommendations — was nowhere to be seen. The CDC, a $9.2 billion-a-year agency tasked with reviewing life-saving vaccines, monitoring diseases and watching for budding threats to Americans' health, is without a clear leader. 'I've been disappointed that we haven't had an aggressive director since — February, March, April, May — fighting for the resources that CDC needs,' said Dr. Robert Redfield, who served as CDC director under the first Trump administration and supported Kennedy's nomination as the nation's health secretary. $9.2 billion-a-year agency without leader as nomination awaits The leadership vacuum at a foremost federal public health agency has existed for months, after President Donald Trump suddenly withdrew his first pick for CDC director in March. A hearing for his new nominee — the agency's former acting director Susan Monarez — has not been scheduled because she has not submitted all the paperwork necessary to proceed, according to a spokesman for Sen. Bill Cassidy, R-La., who will oversee the nomination. HHS did not answer written questions about Monarez's nomination, her current role at the CDC or her salary. An employee directory lists Monarez, a longtime government employee, as a staffer for the NIH under the Advanced Research Projects Agency for Health. Redfield described Kennedy as 'very supportive' of Monarez's nomination. Instead, a lawyer and political appointee with no medical experience is 'carrying out some of the duties' of director at the agency that for seven decades has been led by someone with a medical degree. Matthew Buzzelli, who is also the chief of staff at the CDC, is 'surrounded by highly qualified medical professionals and advisors to help fulfill these duties as appropriate,' Andrew Nixon, an HHS spokesperson said in a statement. Adding to the confusion was an employee-wide email sent last week that thanked 'new acting directors who shave stepped up to the plate.' The email, signed by Monarez, listed her as the acting director. It was was sent just days after Kennedy said at a Senate hearing that Monarez had been replaced by Buzzelli. The lack of a confirmed director will be a problem if a public health emergency such as the COVID-19 pandemic or a rapid uptick in measles cases hits, said Michael Osterholm, an epidemiologist at the University of Minnesota. 'CDC is a crisis, waiting for a crisis to happen,' said Osterholm. 'At this point, I couldn't tell you for the life of me who was going to pull what trigger in a crisis situation.' An acting director rarely seen, and stalled decisions At CDC headquarters in Atlanta, employees say Monarez was rarely heard from between late January – when she was appointed acting director – and late March, when Trump nominated her. She also has not held any of the 'all hands' meetings that were customary under previous CDC chiefs, according to several staffers. One employee, who insisted on anonymity because they were not authorized to speak to the media and fears being fired if identified said Monarez has been almost invisible since her nomination, adding that her absence has been cited by other leaders as an excuse for delaying action. The situation already has led to confusion. In April, a 15-member CDC advisory panel of outside experts met to discuss vaccine policy. The panel makes recommendations to the CDC Director, who routinely signs off on them. But it was unclear during the meeting who would be reviewing the panel's recommendations, which included the expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. HHS officials said the recommendations were going to Buzzelli, but then weeks passed with no decision. A month after the meeting ended, the CDC posted on a web site that Kennedy had signed off on recommendations for travelers against chikungunya, a viral disease transmitted to humans by mosquitos. But there continues to be no word about a decision about the other vaccine recommendations. Controversial COVID-19 vaccine recommendations bypassed CDC panel The problem was accentuated again last week, when Kennedy rolled out recommendations for the COVID-19 vaccine saying they were no longer recommended for healthy children or pregnant women, even though expectant mothers are considered a high-risk group if they contract the virus. Kennedy made the surprise announcement without input from the CDC advisory panel that has historically made recommendations on the nation's vaccine schedule. The CDC days later posted revised guidance that said healthy kids and pregnant women may get the shots. Nixon, the HHS spokesman, said CDC staff were consulted on the recommendations, but would not provide staffer's names or titles. He also did not provide the specific data or research that Kennedy reviewed to reach his conclusion on the new COVID-19 recommendations, just weeks after he said that he did not think 'people should be taking medical advice' from him. 'As Secretary Kennedy said, there is a clear lack of data to support the repeat booster strategy in children,' Nixon said in a statement. Research shows that pregnant women are at higher risk of severe illness, mechanical ventilation and death, when they contract COVID-19 infections. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. Vaccinations also have been recommended for pregnant women because it passes immunity to newborns who are too young for vaccines and also vulnerable to infections. Nixon did not address a written question about recommendations for pregnant women. Kennedy's decision to bypass the the advisory panel and announce new COVID-19 recommendations on his own prompted a key CDC official who works with the committee – Dr. Lakshmi Panagiotakopoulos – to announce her resignation last Friday. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population, and that is not something I am able to continue doing in this role,' she wrote in an email seen by an Associated Press reporter. Signs are mounting that the CDC has been 'sidelined' from key decision-making under Kennedy's watch, said Dr. Anand Parekh, the chief medical adviser for The Bipartisan Policy Center. 'It's difficult to ascertain how we will reverse the chronic disease epidemic or be prepared for myriad public health emergencies without a strong CDC and visible, empowered director,' Parekh said. 'It's also worth noting that every community in the country is served by a local or state public health department that depends on the scientific expertise of the CDC and the leadership of the CDC director.'
Globe and Mail
16 hours ago
- Globe and Mail
$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
$NRXP Has $7.8 Million in Financing for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC). Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine. Current Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC. Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term. Agreement to Purchase Kadima Neuropsychiatry Institute Expected to Serve as Clinical Model for Treatment Offerings Nationwide. Kadima is a Leading Investigative Site for CNS and Psychedelic Research, Having Served as the Lead Site in Nearly All Major Trials in This Space. Dr. David Feifel, Nationally Recognized Pioneer in Interventional Psychiatry to join as Chief Medical Innovation Officer. New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine. Patent expected to be Orange Book Listable. Waiver Exemption from Paying a $4.3 Million New Drug Application Fee Under Prescription Drug User Fee Act (PDUFA). Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties. Application to Uplist to NASDAQ Global Market from NASDAQ Capital Market NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI. NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year. This represents a $3-5 billion market at expected pricing. Based on the data in the trials referenced above, the Company's regulatory counsel encouraged the Company to file an NDA for suicidal depression for NRX-100. In a January 2025 report, respected investment analysis firm D. Boral Capital assigned NRXP a $31 Price Target. The full report may be viewed at this link: Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine On June 5th NRXP announced the transmission of its Abbreviated New Drug Application (ANDA) for electronic filing to the U.S. Food and Drug Administration (FDA) for NRX-100, its preservative-free IV ketamine formulation, for use in all existing approved indications such as anesthesia and pain management. NRXP anticipates filing a citizen's petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use. NRXP believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of closely related benzalkonium chloride in current drug products. Preservatives were originally added to sterile injectable products in an era when a single vial of medication was used to treat multiple patients, a practice no longer allowed in US hospitals. NRXP has demonstrated that there is no need for such preservatives to maintain stability and sterility in ketamine presentations intended for single-patient use. Should the citizen's petition be granted, all formulations of ketamine sold in the US could face a regulatory requirement to be preservative free. $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital. HOPE's three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE's parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression. Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the NRXP HOPE Network of Interventional Psychiatry Clinics On May 13th NRXP announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in NRXP HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy. Kadima is one of California's flagship interventional psychiatry clinics and was among the first to bring ketamine treatment for central nervous system (CNS) disorders out of academic research settings and into clinical practice. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, transcranial magnetic stimulation ("TMS") as well as medication management. Further, Kadima and David Feifel, MD PhD, Founder and Medical Director of Kadima, have served as leaders in clinical trial work on emerging therapies in CNS for top companies in the industry. Importantly, the clinic is profitable and is forecast to continue growth going forward. Dr. Feifel will join NRXP HOPE as its first Chief Medical Innovation Officer upon closing of the acquisition. Patent Application Filed for NRX-100 Proprietary, Preservative Free Formulation of IV Ketamine On May 5th NRXP announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation for the treatment of suicidal depression. The application discloses pharmaceutical compositions, methods of treatment and methods of manufacture and currently includes twenty claims. While subject to the patent review process of the US Patent and Trademark Office, if granted, the patent would provide NRX-100 exclusivity into 2045. This patent filing builds on the NRXP recently initiated filing of an NDA for NRX-100 and its prior Fast Track Designation, with NRX-101, from the FDA. If granted, the patent will help protect the innovation behind this formulation as NRXP advances its commercialization strategy. "We are committed to delivering safer, more effective treatments for patients with suicidal depression," said Jonathan Javitt MD MPH, CEO of NRXP. "NRX-100 eliminates the need for benzethonium chloride, a compound with well-documented safety concerns, and reflects our belief that patients in crisis deserve therapies formulated with their long-term well-being in mind. With the recent FDA fee waiver now in place, we remain on track to complete our NDA submission this quarter — a critical step toward bringing this innovation to patients in need." FDA Award of Filing Fee Waiver for Upcoming NRX-100 (preservative free ketamine) New Drug Application to Treat Patients with Suicidal Depression On April 30th NRXP announced the grant of a filing fee waiver by the US Food and Drug Administration ("FDA") to exempt the Company from a $4.3 million fee to file its New Drug Application for NRX-100 (preservative-free ketamine). The waiver is granted at the discretion of the FDA to Small Business Entities and for drugs that are deemed to be necessary for Public Health. NRXP anticipates that this waiver enables the completion of its New Drug Application for NRX-100 with currently-available corporate resources. The NDA filing is anticipated by the end of the second quarter of this year (Q2 2025). Disclosure listed on the CorporateAds website Media Contact Company Name: NRx Pharmaceuticals, Inc. Contact Person: Matthew Duffy, Chief Business Officer Email: Send Email Phone: 484 254 6134 Address: 1201 Orange Street Suite 600 City: Miami State: Florida Country: United States Website:
